Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emactuzumab vs. Placebo in Tenosynovial Giant Cell Tumour
NCT05417789Phase 3Active, not recruiting
- Sponsor
- SynOx Therapeutics
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of emactuzumab in tenosynovial giant cell tumor (TGCT), sponsored by SynOx Therapeutics. Started Oct 2024; status: active, not recruiting.
02
Drugs
emactuzumab
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT05417789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417789.